11Oct

Bottom Line

Three independent 2026 surveys agree on the direction, even though they report different numbers: employer coverage of GLP-1 medications for weight loss is retrenching, not expanding, as the drugs’ cost collides with the size of the eligible population. Several large, recognizable employers have dropped or are dropping coverage this year. For patients whose insurance no longer covers these medications, a physician-supervised, self-pay program remains a structured path to treatment — which is the model BeLite has always offered.

Background

When semaglutide and tirzepatide first reached the market for weight management in 2022–2023, employer coverage decisions were close to a coin flip. Three years in, with GLP-1 drugs now consuming a rapidly growing share of pharmacy budgets, a clearer and less favorable pattern has emerged across every major 2026 survey of employer benefits.

What the Surveys Found

A Business Group on Health survey of large employers, reported by Modern Healthcare and summarized in KFF Health News’s September 8, 2026 Morning Briefing, found that only 60% of large employers now offer GLP-1 coverage for weight loss, down sharply from 72% in 2025. Cigna Group and PricewaterhouseCoopers were named as having already eliminated coverage, with PepsiCo and Starbucks reported to be following suit in October 2026 — the same month this brief’s coverage window sits just ahead of.

A separate interview at the Pharmacy Benefit Management Institute’s 2026 conference, published by Managed Healthcare Executive on September 23, 2026, quantified the shift inside one large benefits consultancy’s own book of business: Employers Health, which manages about $6 billion in pharmacy spending across roughly 500 self-insured employer clients, now sees about 65% of those clients excluding GLP-1s for obesity — up from roughly a 50/50 split when the drugs launched in 2022–2023. Clinical advisor Alexis Sova, PharmD, MBA, attributed the pullback primarily to “the size of the population eligible for GLP-1s combined with the drugs’ current price point,” while noting that cardiometabolic and cardiovascular benefits remain widely recognized industry-wide.

A broader membership survey by the International Foundation of Employee Benefit Plans, published July 7, 2026, tells a more mixed story from a wider, less large-employer-skewed population: 60% of employers now cover GLP-1s for diabetes only (up from 55% in 2025), while coverage for both diabetes and weight loss has been flat at 36% since 2025. Only 9% of employers currently excluding weight-loss coverage say they’re considering adding it. The same survey found GLP-1 drugs’ share of annual pharmacy claims has climbed from 6.9% in 2023 to 11.4% in 2026 — the cost pressure driving all three surveys’ findings.

Limitations

  • These are three different survey populations with different definitions of “coverage” and different employer sizes — they should not be read as three measurements of one national number. The Business Group on Health and Employers Health figures skew toward large, self-insured employers; the IFEBP figure includes a broader range of plan sizes and shows a less dramatic pullback.
  • Coverage decisions vary by plan year and open-enrollment cycle; a figure reported in September reflects decisions already locked in for 2026 and intentions for 2027, which can still change before enrollment finalizes.
  • None of these surveys capture individual plan design details (prior authorization, step therapy, BMI thresholds) that often matter as much as a blunt “covered/not covered” label.

BeLite Clinical Perspective

This trend doesn’t change the medical case for these medications — it changes how patients pay for them. For patients whose employer has dropped coverage, or who never had it, a physician-supervised, self-pay weight-management program is a well-established alternative, not a downgrade: it typically includes the clinical oversight, lab monitoring, and dose titration that a pharmacy benefit alone doesn’t provide. BeLite’s consultations are free regardless of insurance status, which matters most for exactly the patients this trend affects — people trying to figure out their options after a coverage change. For a fuller look at the medications themselves and how dosing and cost compare across options, see our medications overview.

FAQs

Q: My employer just dropped GLP-1 coverage. What are my options?

A: A physician-supervised, self-pay weight-management program is the most structured alternative — it typically includes clinical monitoring that a pharmacy benefit alone doesn’t provide. It’s worth having a consultation to understand actual out-of-pocket costs for your situation, since list price, manufacturer savings programs, and compounded alternatives all carry very different costs and risks.

Q: Why are employers dropping coverage if the drugs work?

A: The surveys cited above point to cost, not effectiveness, as the driver — the combination of a large eligible population and the drugs’ price has made the benefit expensive at scale, even though cardiometabolic benefits are widely recognized.

Q: Is coverage for diabetes affected the same way as coverage for weight loss?

A: No. The IFEBP survey found diabetes-only coverage has actually grown (55% to 60% year over year), while weight-loss coverage has stayed flat or declined depending on the survey. Employers appear to be drawing a sharper line between the two uses.

Q: Does losing employer coverage mean I have to stop my medication?

A: Not necessarily, but it does mean the cost structure changes. This is a conversation to have with your prescribing physician about manufacturer savings programs, dose/formulation options, and whether a self-pay program fits your situation before making any decision about stopping.

References

  1. KFF Health News. Morning Briefing: Healthcare Costs. September 8, 2026 (summarizing Modern Healthcare’s reporting on the Business Group on Health employer survey).
  2. Managed Healthcare Executive. Alexis Sova, Pharm.D., MBA, on Employers Pulling Back on GLP-1 Coverage (PBMI 2026). September 23, 2026.
  3. International Foundation of Employee Benefit Plans. GLP-1 Drugs Survey Report: What Employers Are and Aren’t Covering in 2026. July 7, 2026.
  4. BeLite Medical Center. Our Medications.
10Oct

Bottom Line

A large real-world study published in January 2026 found that people with type 2 diabetes on tirzepatide had a lower rate of newly diagnosed dementia over two years than people on semaglutide or on SGLT2 inhibitors, and that semaglutide also outperformed SGLT2 inhibitors. The differences are real and statistically significant, but this is an observational comparison of medical records, not a randomized trial designed to answer this question — so it should inform curiosity and conversation with a physician, not a decision to switch medications for brain-health reasons alone.

Background

GLP-1 receptor agonists cross into the brain and interact with insulin signaling and inflammation pathways, which has driven a wave of interest in whether they affect dementia risk independent of weight loss. Most of the prior evidence has come from post-hoc analyses of diabetes and cardiovascular trials not designed to study cognition. This new paper by Younis and colleagues, published online January 14, 2026 in Diabetes Research and Clinical Practice, takes a different approach: three separate “target trial emulations” — a method that uses real-world medical record data to approximate what a randomized trial would show by carefully matching patients on their baseline characteristics before comparing outcomes.

What the Study Found

  • Data source: TriNetX, a federated network drawing on more than 150 million patient records across more than 140 healthcare organizations.
  • Population: Adults with type 2 diabetes who had no dementia diagnosis at baseline, followed for two years after starting one of the compared medications.
  • Tirzepatide vs. semaglutide: 12,246 matched patients per arm. Tirzepatide was associated with a 31% lower hazard of incident dementia (HR 0.69, 95% CI 0.48–0.99, p=0.04).
  • Tirzepatide vs. SGLT2 inhibitors: 14,462 matched patients per arm. Tirzepatide showed a 34% lower hazard (HR 0.66, 95% CI 0.47–0.93, p=0.02).
  • Semaglutide vs. SGLT2 inhibitors: 57,959 matched patients per arm — by far the largest comparison. Semaglutide showed a 29% lower hazard (HR 0.71, 95% CI 0.63–0.78, p<0.01).
  • All-cause mortality: Tirzepatide and semaglutide were both associated with lower mortality than SGLT2 inhibitors, and tirzepatide lower than semaglutide (HR 0.72, 95% CI 0.58–0.90) — though the authors specifically flagged the tirzepatide-vs-SGLT2i mortality comparison as one where their own sensitivity analysis (E-values) suggests unmeasured confounding could plausibly explain some or all of the effect size.

Limitations

  • This is an observational, retrospective comparison of electronic health records, not a randomized controlled trial. Target trial emulation is a rigorous way to minimize bias in that kind of data, but it cannot fully rule out confounding — for example, if healthier or more health-engaged patients are more likely to be prescribed tirzepatide in the first place, that alone could produce a result like this.
  • Two years of follow-up is short for a disease like dementia that typically develops over a decade or more; the result shows what happened in that window, not necessarily the medication’s long-term effect on dementia risk.
  • The population is adults with type 2 diabetes, not people using these medications solely for weight management without diabetes — the results may not generalize to BeLite’s non-diabetic weight-loss patients.
  • The authors describe their own findings as hypothesis-generating and explicitly call for confirmation in randomized controlled trials before any clinical recommendation should change.

BeLite Clinical Perspective

This study is a reason for cautious optimism, not a reason to change anyone’s medication. Patients already being counseled on tirzepatide vs. semaglutide — for example using the comparative efficacy data in our head-to-head comparison of the two drugs — may reasonably ask about this result, and it’s fair to tell them the directional signal is encouraging and consistent with what’s known about GLP-1 receptor agonists and neuroinflammation. It is not, on its own, grounds to switch medications purely for brain-health reasons, particularly for patients doing well on their current regimen. For patients also asking about long-term cardiovascular outcomes on tirzepatide, our 3-year SURMOUNT-1 cardiovascular risk analysis is a useful companion read — both pieces point toward the same theme, that tirzepatide’s benefits may extend meaningfully beyond the number on the scale, while being clear that neither is a substitute for an individualized conversation with your prescribing physician.

FAQs

Q: Does this mean tirzepatide prevents dementia?

A: No. The study shows an association — people taking tirzepatide had fewer new dementia diagnoses than comparison groups over two years — but it cannot prove the medication caused that difference. Dementia risk is influenced by many factors the study could not fully control for.

Q: Should I switch from semaglutide to tirzepatide because of this study?

A: Not based on this alone. The result is interesting but preliminary, and switching medications involves other considerations — tolerability, cost, insurance coverage, and how well you’re responding to your current treatment. Talk to your prescribing physician before making any change.

Q: Does this apply to people who don’t have diabetes?

A: The study population was adults with type 2 diabetes. Many BeLite patients use these medications for weight management without diabetes, and the results haven’t been specifically studied in that group, so they should be read as suggestive rather than directly applicable.

Q: Why did SGLT2 inhibitors come out worse in this comparison?

A: The study compared the three drug classes to each other, not to no treatment. SGLT2 inhibitors are effective, well-studied diabetes medications in their own right; this result says the two GLP-1-based therapies were associated with a lower dementia rate than SGLT2 inhibitors in this particular dataset, not that SGLT2 inhibitors are unsafe.

Q: Is this the first study to look at GLP-1 drugs and dementia?

A: No — it adds to a growing body of research, including prior analyses suggesting lower stroke and dementia-related outcomes with semaglutide and tirzepatide in people with diabetes and obesity. This study’s target trial emulation design is a methodological step up from many earlier post-hoc analyses, but all of this research is still observational.

References

  1. Younis A, Henney AE, Riley DR, et al. Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: real-world evidence from a retrospective cohort study. Diabetes Res Clin Pract. 2026;235:113083.
  2. BeLite Medical Center. Tirzepatide vs. Semaglutide: Which Weight Loss Drug Works Better? [May 2025 NEJM Study Explained]
  3. BeLite Medical Center. Does Tirzepatide Lower Cardiovascular Risk? What the 3-Year SURMOUNT-1 Analysis Actually Shows.
  4. BeLite Medical Center. Our Medications.
9Oct
  1. Employers are dropping GLP-1 weight-loss coverage

Three 2026 surveys point the same way. A Business Group on Health survey found 60% of large employers now cover GLP-1s for weight loss, down from 72% in 2025, with Cigna and PwC already out and PepsiCo and Starbucks following in October. Employers Health says about 65% of its roughly 500 self-insured clients now exclude them. Surveys use different employer groups, so the numbers aren’t directly comparable.

What it means for patients: If your coverage changed, you still have options. BeLite consultations are free, and we can walk through costs with you.

Source: KFF Health News, Sept 8, 2026  ·  Managed Healthcare Executive, Sept 23, 2026

  1. Tirzepatide and semaglutide linked to lower dementia diagnoses in diabetes

A real-world study of people with type 2 diabetes found tirzepatide had a lower two-year dementia rate than semaglutide (HR 0.69) or SGLT2 inhibitors (HR 0.66); semaglutide also beat SGLT2 inhibitors (HR 0.71). This is observational, not a randomized trial, and the authors call it hypothesis-generating.

What it means for patients: Interesting, but not a reason to switch medications. Results in people without diabetes haven’t been studied.

Source: Younis et al., Diabetes Res Clin Pract 2026

  1. GLP-1 prescribing to young children is rising fast

A Pediatrics study published Sept 4 found annual GLP-1 prescribing among children 8–11 with obesity rose from 0.03% in 2019 to 9.3% in 2026, a 310-fold increase. STAT News reports trials now include children as young as 6. No GLP-1 is FDA-approved for obesity under age 12.

What it means for patients: For parents, this is a decision for a pediatrician or pediatric obesity specialist, not a general recommendation.

Source: Orandi et al., Pediatrics 2026  ·  STAT News, Sept 15, 2026

  1. Watch list: CagriSema still awaiting an FDA decision

Novo Nordisk filed in December 2025 and a decision is expected in the fourth quarter of 2026. As of October 6 there is no approval. Retatrutide is not expected to be filed until Q1 2027 and can’t legally be prescribed or compounded.

What it means for patients: If anyone tells you either drug is available now, be skeptical. See our own CagriSema REDEFINE trials review.

Source: FDA status checked Oct 6, 2026

 

Go deeper

Full articles on items 1–3 are in this week’s Research Brief. Our existing guides: Our Medications  ·  What happens after stopping Wegovy or Zepbound  ·  Does tirzepatide lower cardiovascular risk?

[Publishing note: once the three new articles are live, link items 1–3 to them directly.]

How BeLite Can Help

BeLite Medical Center has provided physician-supervised weight management in Fairfax, Virginia since 1995. New-patient consultations are free. Call or text (703) 359-9200.

Medical disclaimer: This content is for educational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed physician before starting, stopping, or changing any medication.

8Oct

Bottom Line

GLP-1 medications are being prescribed to young children with obesity far more than they were even a few years ago, and clinical trials are now testing them in children as young as 6. But approval and evidence have not kept pace with use: no GLP-1 medication is currently FDA-approved for obesity treatment in children younger than 12, and only semaglutide and liraglutide are approved for ages 12 and older. Prescribing in children 8–11 remains uncommon in absolute terms but has risen sharply and is concentrated in the most clinically severe cases — both reassuring and a reason for careful, individualized decision-making rather than a blanket answer.

What’s Actually Approved Right Now

  • Semaglutide (Wegovy): approved for chronic weight management in adolescents ages 12 and older, based on the STEP TEENS trial.
  • Liraglutide (Saxenda, and a 2025-approved generic): approved for ages 12–17 with body weight over 60 kg and obesity, and for adults. Not approved, and not established as safe or effective, in children under 12.

Tirzepatide (Zepbound): approved for adults only — there is no pediatric obesity approval. A separate tirzepatide product, Mounjaro, is approved for type 2 diabetes in patients 10 and older, a different indication that should not be confused with weight-loss use.

  • Bottom line on age 12: this is the current floor for any FDA-approved GLP-1 obesity treatment. Anything used below that age is, by definition, off-label or investigational.

What the New Pediatric Trial Data Show

The most direct evidence in children under 12 comes from the SCALE Kids trial, published in the New England Journal of Medicine. This placebo-controlled study randomized 82 children ages 6 to under 12 with obesity to liraglutide or placebo for 56 weeks. Children on liraglutide had a mean body-weight change of +1.6% (essentially holding steady while growing), compared with +10.0% in the placebo group — a meaningful difference, since children are still growing and some weight gain is expected. A clinically meaningful BMI reduction of 5% or more occurred in 46% of the liraglutide group versus 9% on placebo. Gastrointestinal side effects were more common with liraglutide (80% vs. 54% of participants), and the trial was not large or long enough to evaluate rare risks or effects on lean body mass and growth.

This trial supports the biological plausibility of GLP-1 treatment in younger children, but a single 56-week study of 82 children is not the same as an approved, well-characterized treatment. A separate completed safety and pharmacokinetics study of tirzepatide in children ages 6–11 has examined dosing in that age group without establishing an approved use. STAT News reported on September 15, 2026 that additional companies are now planning or running obesity-drug trials in children as young as 6 — meaning more data, but also more years before any of it could become an approved treatment.

What the Prescribing Data Show Today

A study published September 4, 2026 in Pediatrics used electronic health records covering more than 3.5 million children ages 8 to 11 with obesity (and without diabetes) to track GLP-1 prescribing from 2019 through mid-2026. Two figures matter and answer different questions. The annual prescribing rate — the share of children in that age group prescribed a GLP-1 medication during a given year — rose from 0.03% in 2019 to 9.3% in 2026, a 310-fold increase. Looked at cumulatively over the full study period, 20,282 children ages 8–11 (0.6% of the total cohort) received at least one GLP-1 prescription, compared with 0.9% of adolescents ages 12–17 in the same health system data. Put plainly: use remains uncommon in absolute numbers, but the rate of new prescribing has grown extremely quickly.

  • Prescribing was concentrated in higher-severity cases: 93.7% of the 8–11 group who received a GLP-1 had severe obesity, 65.2% had at least one weight-related comorbidity, and roughly a quarter had prediabetes.
  • Prescribing was not evenly distributed by income: children in higher-income communities were prescribed GLP-1 medications at a 55% higher rate than those in lower-income communities — an access and equity question worth watching.
  • Since none of these medications are approved for children under 12, virtually all of this prescribing in the 8–11 age group is necessarily off-label.

Limitations

  • Long-term effects on growth, bone development, puberty, and lean body mass have not been established in large, long-duration pediatric trials.
  • What happens when a child stops treatment — whether weight regain patterns mirror those seen in adults — is not yet well characterized in this age group.
  • Optimal duration of treatment in a still-growing child is an open clinical question, not a solved one.
  • Psychological and behavioral effects of early pharmacologic treatment for a chronic condition are an active area of research, not a settled finding.

BeLite Clinical Perspective

BeLite is a physician-supervised weight management practice for adults, and we do not market or provide services directly to young children. For families weighing pharmacologic treatment for a child under 12, our honest guidance is the same standard that applies to any off-label, still-evolving area of medicine: this decision belongs with a pediatrician or pediatric obesity specialist who can weigh your child’s specific health picture, monitor growth and development over time, and stay current with a fast-moving evidence base. For older teens and adults in the household considering GLP-1 treatment for themselves, the approved-medication evidence is far more mature — our guides to what to expect after stopping treatment and protecting muscle during weight loss cover that ground in detail.

FAQs

Q: Is Wegovy or Zepbound approved for young children?

A: No. Semaglutide (Wegovy) is approved starting at age 12. Zepbound (tirzepatide) has no pediatric obesity approval at any age. No GLP-1 medication is approved for obesity treatment in children under 12.

Q: My child’s doctor is considering a GLP-1 for my 9-year-old — is that appropriate?

A: It would be off-label use. Some pediatric obesity specialists consider it in children with severe obesity and significant health complications, under close supervision, but this is an individualized decision that belongs with a pediatrician or pediatric obesity specialist familiar with your child’s full health picture — not a general recommendation.

Q: How common is this really?

A: Still uncommon in absolute terms — roughly 0.6% of children 8–11 with obesity had ever received a GLP-1 prescription through mid-2026 — but the annual rate of new prescribing has risen 310-fold since 2019, concentrated in the most severe cases.

Q: Are trials testing these drugs in even younger children?

A: Yes. As of September 2026, companies are running or planning trials in children as young as 6, following the published SCALE Kids trial in children ages 6 to under 12.

References

  1. Fox CK, Barrientos-Pérez M, Bomberg EM, et al. Liraglutide for children 6 to <12 years of age with obesity — a randomized trial (SCALE Kids). N Engl J Med. 2024. PMID 39258838.
  2. Orandi BJ, Patel SS, Messito MJ, et al. Trends in GLP-1 receptor agonist prescriptions for children ages 8 to 11 with obesity: 2019–2026. Pediatrics. 2026;e2026077048.
  3. STAT News (The Readout). Obesity drugmakers are testing them in children as young as 6. September 15, 2026.
  4. BeLite Medical Center. Zepbound.
  5. BeLite Medical Center. Our Medications.
  6. BeLite Medical Center. What Happens After Stopping Wegovy or Zepbound?
  7. BeLite Medical Center. GLP-1 Muscle Loss: How Much Lean Mass Is Lost?

 

10Sep

You lost the weight. Why does your face look older?

It’s one of the most common — and least discussed — experiences our weight loss patients describe: the scale says success, but the mirror shows a face that looks deflated, hollowed, or suddenly older. The phenomenon has a popular name, “Ozempic face,” and it’s now the subject of a growing medical literature, including a 2025 systematic review documenting the exaggerated facial volume loss that can accompany GLP-1–driven weight loss. As a medical practice that has guided thousands of patients through semaglutide and tirzepatide treatment, we’d rather explain honestly what’s happening — and what each treatment can and cannot do about it — than sell you a one-size-fits-all fix.

What’s actually happening to your face

Facial fat isn’t just “weight” — it’s structural. Distinct fat compartments support the skin, round out the cheeks and temples, and smooth the transitions between facial regions. When weight comes off quickly, those compartments deflate along with the rest of your body fat. A 2026 anatomical review describes the pattern: deflation of the superficial fat compartments (especially in the midface), reduced deep support, and increased skin laxity — flattening contours and making transition lines more pronounced. Clinical estimates cited in the ophthalmic-plastics literature suggest roughly 7% of midfacial volume is lost for every 10 kilograms (about 22 pounds) of weight lost. Importantly, this isn’t a drug side effect in the usual sense — it’s the face’s share of rapid fat loss, the same phenomenon long described after bariatric surgery. Slower weight loss tends to mean gentler facial change, one more reason we favor medically supervised, gradual protocols.

Matching the treatment to the problem

Different tools address different parts of this picture, and honest scoping matters more here than anywhere else in aesthetics:

  • Volume loss (hollowing, flattened cheeks): this is the territory of dermal fillers and collagen-stimulating injectables, which the anatomical literature identifies as the evidence-based response to compartment deflation. BeLite does not currently offer fillers — if volume restoration is your priority, we’ll say so plainly and you should see a practice that does.
  • Skin laxity (sagging): addressed with skin-tightening technologies or, in significant cases, surgery — also outside what a neurotoxin can do.
  • Lines made more prominent by deflation: this is where Xeomin fits. As volume decreases, forehead lines, frown lines, and crow’s feet often stand out more — the skin creases more visibly over thinner support. Relaxing the muscles that create those lines softens one of the most visible components of the post-weight-loss face. It will not re-inflate anything, and we won’t tell you it will.

The whole-picture approach

Because facial change tracks the pace and magnitude of weight loss, the conversation belongs inside your weight loss care, not bolted on afterward. That’s the advantage of addressing it at the practice that manages your GLP-1 treatment: we can moderate the rate of loss, protect muscle and nutrition along the way (see our guides to preserving muscle during GLP-1 treatment and what happens to body composition — [developer: link existing posts]), and time any aesthetic treatment sensibly — usually once weight has stabilized, since a face still changing is a moving target.

FAQ

Does Xeomin treat Ozempic face? It treats one component: the expression lines that volume loss makes more prominent. It does not restore volume — fillers and collagen stimulators address that.

Will my face recover if I stop the medication? Regaining weight regains some facial fat, but that’s not a treatment strategy — it trades away the health benefits you earned. Stabilizing at your goal weight and addressing specific concerns directly is the sounder path.

Can I prevent it? Gradual, supervised weight loss with adequate protein and strength training gives your skin the best chance to adapt. This is a core part of how we run GLP-1 treatment at BeLite.

Wondering whether Xeomin is right for you? BeLite Medical Center has served Fairfax and Northern Virginia since 1995. Consultations are free — your provider will develop an individualized treatment plan with you, and if you decide not to proceed, you pay nothing. Schedule online 24/7, or call or text (703) 359-9200.

This article is for general education and is not medical advice. Individual results vary. Talk with a licensed medical provider about whether treatment is appropriate for you. Botox® is a registered trademark of Allergan, an AbbVie company; Xeomin® is a registered trademark of Merz Pharma. BeLite Medical Center is not affiliated with Allergan or AbbVie.

References (verified, hyperlinked)

  • Daneshgaran G, Shauly O, Gould DJ. “Ozempic Face” in plastic surgery: a systematic review. Aesthet Surg J Open Forum. 2025;7:ojaf056. PMID 40626110
  • GLP-1–induced weight loss and the face: anatomical mechanisms and rationale for collagen-stimulating and volumizing treatments (2026 review). PMID 42210888
  • American Academy of Ophthalmology, EyeNet. GLP-1s and rapid facial aging: aesthetic solutions (clinical summary incl. midfacial volume data). org
9Sep

The honest answer: $10 to $20 per unit

If you’ve tried to price neurotoxin treatment in Northern Virginia, you’ve probably noticed that most practices won’t tell you — the price is hidden behind a consultation. Here’s the honest landscape: published per-unit prices in the Fairfax area generally run from about $10 to $20, with most established practices in the $12–$15 range and dermatology or plastic-surgery offices at the top of the band. At BeLite, we publish our price: Xeomin — a comparable FDA-approved alternative to Botox — is $12.50 per unit, and consultations are free.

Per-unit vs. per-area pricing: read the fine print

Practices price neurotoxins two ways. Per-unit pricing (what we use) means you pay for exactly the amount of product injected — transparent and directly comparable between practices. Per-area pricing (“forehead: $350”) bundles an unstated number of units; it can be fine, but it makes comparison shopping impossible and sometimes hides conservative dosing that fades early. When comparing quotes, always ask: how many units, and what’s the per-unit math?

What a realistic treatment actually costs

Because every face is different, your total depends on the individualized treatment plan you develop with your medical provider — at BeLite, typically between $400 and $700 depending on how many units your plan calls for. You pay only for the units used. Be cautious of any practice that quotes a total price before anyone has examined your facial movement.

Why suspiciously cheap neurotoxin is a red flag

When you see prices dramatically below the local range — or injections offered at homes, parties, or unlicensed storefronts — the discount usually comes from somewhere you don’t want it to. In 2024, the FDA alerted the public that counterfeit “Botox” had been found in multiple states, with adverse events including hospitalizations. The CDC’s investigation documented 17 people across 9 states with harmful reactions — 13 of them hospitalized — after injections with counterfeit or unverified products, typically administered by unlicensed or untrained individuals outside healthcare settings, and continued to receive similar reports afterward. As recently as November 2025, the FDA issued warning letters to 18 websites selling unapproved injectables. Legitimate product can only be purchased by licensed medical practices from authorized distributors — which is one structural reason properly sourced treatment can’t be $6 a unit.

Questions that protect you (at any practice)

  • What product is this, exactly — and was it purchased from the manufacturer’s authorized U.S. distributor?
  • What is your per-unit price, and how many units does my plan call for?
  • Who is injecting me, and what license do they hold?
  • Is there a consultation fee, and am I committed to anything before we agree on a plan?

FAQ

Why is Xeomin cheaper than some Botox quotes if it works the same? Manufacturing and distribution economics differ between products; comparable results don’t require identical wholesale costs. We pass the difference on.

Is cheaper always worse? No — within the normal local range, price differences mostly reflect overhead and brand. Below the normal range is where the red flags start.

Do you charge for a consultation? No. Consultations at BeLite are free, and you pay nothing if you decide not to proceed.

Wondering whether Xeomin is right for you? BeLite Medical Center has served Fairfax and Northern Virginia since 1995. Consultations are free — your provider will develop an individualized treatment plan with you, and if you decide not to proceed, you pay nothing. Schedule online 24/7, or call or text (703) 359-9200.

This article is for general education and is not medical advice. Individual results vary. Talk with a licensed medical provider about whether treatment is appropriate for you. Botox® is a registered trademark of Allergan, an AbbVie company; Xeomin® is a registered trademark of Merz Pharma. BeLite Medical Center is not affiliated with Allergan or AbbVie.

References (verified, hyperlinked)

  • Counterfeit version of Botox found in multiple states (Apr 16, 2024). fda.gov
  • Investigation update: harmful reactions linked to counterfeit “Botox” (17 people, 9 states; closed Jun 2024). cdc.gov · Dec 2024 update

FDA warning letters to 18 websites selling unapproved injectables (Nov 2025; legal summary). verrill-law.com